セフロキシム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P272：汚染された作業衣は作業場から出さないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P285：換気が十分でない場合には、呼吸用保護具を着用する こと。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P304+P341：吸入した場合：呼吸が困難な場合には、空気の新鮮な場 所に移し、呼吸しやすい姿勢で休息させること。

  P321：特別な処置が必要である（このラベルの．．． を見よ）。

  P333+P313：皮膚刺激または発疹が生じた場合：医師の診断/手当てを 受けること。

  P342+P311：呼吸に関する症状が出た場合：医師に連絡すること。

  P363：汚染された衣類を再使用す場合には洗濯をすること。

  P501：内容物/容器を．．．に廃棄すること。

セフロキシム 価格

セフロキシム 化学特性,用途語,生産方法

• 効能

  抗生物質, 細胞壁合成阻害薬

• 説明

  Cefuroxime axetil is the acetoxyethyl ester and oral prodrug of cefuroxime, a second-generation cephalosporin. It has a broad spectrum of action and is resistant to most P-lactamases. Cefuroxime axed is indicated for serious bacterial infections, especially where no identification of organism(s) has been made.

• 化学的特性

  white crystalline solid

• 使用

  Cefuroxime is a second-generation cephalosporin antibiotic.

• 主な応用

  Cefuroxime was synthesized by Glaxo Laboratories in 1975 as the first cephem antibiotic with the methoxyimino group at the 7 position. It is highly resistant to hydrolysis by cephalosporinase and is active against a variety of gram-negative bacteria, including indolepositive Proteus, Enterobacter, and Citrobacter. Cefuroxime is considered to be one of the socalled second-generation cephalosporins.

• 定義

  ChEBI: A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.

• 抗菌性

  The methoximino side chain provides stability to most Gram-negative β-lactamases and it is active against most enterobacteria, including many multiresistant strains. Acinetobacter spp., S. marcescens and Ps. aeruginosa are resistant, although some Burkholderia cepacia strains are susceptible. Some anaerobic Gram-negative rods are susceptible, but B. fragilis is resistant. The minimum immobilizing concentration for the Nichol’s strain of T. pallidum is 0.01 mg/L.

• 薬理学

  Cefuroxime acts bactericidally. It has a narrow spectrum of antimicrobial action. It is resistant to beta-lactamase action. It is highly active with respect to Gram-negative microorganisms (intestinal and hemophilial bacilli, salmonella, shigella, enterobacteria, and gonococci). It is also active with respect to Gram-positive microorganisms (staphylococci, streptococci). It is inactive with respect to various types of Pseudomonas, most strains of enterococci, many strains of Enterobacter cloacae, methylcillin-resistant staphylococci, and L. monocytogenes.
  It is used for bacterial infections caused by microorganisms that are sensitive to the drug. These may be abdominal and gynecological infections, sepsis, meningitis, endocarditis, infections of the urinary and respiratory tracts, bones, joints, skin, and soft tissues. It is widely used for pneumonia as well as bacterial meningitis in children, and for post-operational infectious complications. Synonyms of this drug are ceftin, zinacef, curoxim, kefox, and many others.

• 臨床応用

  Cefuroxime axetil (Ceftin) is the 1-acetyoxyethyl ester ofcefuroxime. During absorption, this acid-stable, lipophilic,oral prodrug derivative of cefuroxime is hydrolyzed to cefuroximeby intestinal and/or plasma enzymes. The axetilester provides an oral bioavailability of 35% to 50% of cefuroxime,depending on conditions. Oral absorption of theester is increased by food but decreased by antacids and histamineH2-antagonists. The latter effect may be because ofspontaneous hydrolysis of the ester in the intestine becauseof the higher pH created by these drugs. Axetil is used forthe oral treatment of non–life-threatening infections causedby bacteria that are susceptible to cefuroxime. The prodrugform permits twice-a-day dosing for such infections.

• 副作用

  It is well tolerated with little pain or phlebitis on injection. Minor hypersensitivity reactions and biochemical changes common to cephalosporins are described.
  The axetil ester may cause diarrhea and, in some cases, vomiting. Changes in the bowel flora, sometimes with the appearance of C. difficile, have been reported in about 15% of patients. Vaginitis is reported in about 2% of female patients.

セフロキシム 上流と下流の製品情報

セフロキシム 生産企業

Global(266)Suppliers

55268-75-2, セフロキシム キーワード